Aug 30 (Reuters) - Pfizer Inc said on Monday its drug to treat patients with moderate to severe atopic dermatitis met main goal in a late-stage study and was statistically superior compared to rival from Regeneron. (Reporting by Dania Nadeem in Bengaluru)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
906.5 USD | -0.09% | +0.59% | +3.22% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.22% | 97.5B | |
-1.51% | 105B | |
+1.86% | 22.19B | |
-16.53% | 21.33B | |
-8.49% | 18.68B | |
-42.33% | 16.6B | |
-20.09% | 14.52B | |
+5.47% | 14.09B | |
+28.85% | 10.99B | |
-24.93% | 8.63B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Regeneron Pharmaceuticals : Pfizer's skin disease drug meets main goal in late-stage trial